Drugs / (+)-SJ000557733
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02867059 | Sep → Dec 2016 | Plasmodium falciparum malaria | Medicines for Malaria Venture | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (+)-SJ000557733 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02867059 ↗ |
| Action | Inhibit | “(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage.” NCT02867059 ↗ |
| Route | Oral | “SJ733 hydrochloride salt was formulated as a powder blend in capsules containing 75 mg or 300 mg for oral administration.” PMID 32275867 ↗ Apr 2020 |